Search Results
COVID 19 Focus on High Risk MDS and Secondary AML Patients
Treatment of High Risk MDS and the Indication for Stem Cell Transplant
Conversation with MPN Specialists: Focus on Myelofibrosis
Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?
A Unified Approach to Higher Risk MDS: Standard and Emerging Therapies
Conversation with MPN Specialists: Focus on Essential Thrombocythemia
Anti-TIM-3 antibody sabatolimab + hypomethylating agents for high-risk MDS & AML
MDS Therapies & Options in 2020
Leukemia Committee
Management of Low Risk MDS with Dr. Mikkael Sekeres
Why MPN transforms to AML
Higher-Risk Myelodysplastic Syndromes | David Sallman, MD
